Scholars Central

Review articlePublished 2014

Therapeutic Value of Silymarin as Iron Chelator in Children with Beta Thalassemia with Iron Overload

Authors: Adel A Hagag, Mokhtar Abd Elfatah

Journal of Leukemia

Volume 2 · Issue 2 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Beta thalassemia is an inherited hemoglobin disorder resulting in chronic hemolytic anemia. The most common treatment for thalassemia is blood transfusion which is necessary to provide the patients with healthy red blood cells containing normal hemoglobin. Repeated blood transfusion leads to iron overload. Excess iron is deposited in body organs as liver, heart and endocrine glands causing organ damage. Iron chelation therapy is the main way to treat iron overload in beta thalassemia major. Silymarin and its biologically active component Silybin are strong antioxidant and have documented iron chelating activities in patients with beta-thalassemia major. The aim of this review was to spotlight on the therapeutic value of silymarin as iron chelator in children with beta thalassemia major with iron overload.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Leukemia
  • SubjectHaematology
  • BylineArticles whose byline prints “Adel A Hagag”
  • BylineArticles whose byline prints “Mokhtar Abd Elfatah”